Psychopharmacology Update 2018: Treatment Resistant Bipolar Disorder



Date & Location
Friday, May 10, 2019, 12:00 AM - Sunday, May 10, 2020, 11:59 PM

Credits
AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Target Audience
Specialties - Geriatric Medicine, Neurology and Rehabilitation, Nursing, Pediatrics, Primary Care, Psychiatry and Behavioral Health

Overview

No treatments have been developed specifically for bipolar disorder. Drug development is difficult because the etiology and pathophysiology of bipolar disorder are not understood. and no animal models exist. The illness itself is complex and its presentation is heterogeneous, displaying mania, depression, mixed states, rapid cycling, periods of euthymia, and, in some patients, psychotic symptoms. The mainstay of treatment for bipolar disorder. lithium. was discovered serendipitously 7 decades ago. Other agents efficacious in bipolar disorder are drugs that were developed for other purposes, such as epilepsy and schizophrenia. The effects of these drugs in bipolar disorder are real but modest and adverse events are common. Finding a tolerable combination of drugs and appropriate doses is largely a matter of trial and error. Few comparative studies that can inform clinical decision making have been done. Likewise, there is little evidence to guide clinicians on the subsets of patients that may respond to particular agents. But treatment for patients with bipolar disorder is critical. Bipolar disorder causes a substantial decrease in quality of life. and its comorbid medical disorders decrease life expectancy by 1 to 2 decades. Some patients fail to respond adequately to the standard medications. Additional approaches. supported by a few small trials, may be appropriate for these patients. Clinicians would benefit from education summarizing additional treatment approaches for patients with treatment resistant bipolar disorder. 


Registration

To register and review this FREE enduring material activity go to: 

https://www.globalacademycme.com/cme/psychiatry/treatment-resistant-bipolar-disorder

 Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test. you will be directed to a webpage that will allow you to receive your certificate of credit via email or you may print it out at that time. 

 The on ine post-test and evaluation can be accessed at https://tlnyurl.com(TxReslstBD.
Objectives
At the conclusion of this program, participants should be better able to:

  1. Use the best available evidence to guide selection of pharmacotherapy for first episode mania
  2. Use the best available evidence to guide selection of pharmacotherapy for first episode depression in bipolar disorder

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing education for physicians. 

The University of Cincinnati designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


Additional Information

Disclaimer Statement

The opinions expressed during this activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.